Not Out Of The Dark Yet: UK’s NICE Turns Down Clinuvel’s Phototoxicity Drug Scenesse

NICE has issued a preliminary assessment in which it recommends against public funding in England for Clinuvel’s novel drug Scenesse for the ultra-rare condition, erythropoietic protoporphyria (EPP). The company says it intends to pursue reimbursement in the coming months.